Mirdametinib
| CAS No. | 391210-10-9 | Cat. No. | BCP01841 |
| Name | Mirdametinib | ||
| Synonyms | 870474-62-7;PD 0325901;PD325901;PD-0325901; | ||
| Formula | C16H14F3IN2O4 | M. Wt | 482.19 |
| Description | Mirdametinib is an orally bioavailable, synthetic organic molecule targeting mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. Upon administration, mirdametinib selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors. | ||
| Pathways | MAPK Pathway | ||
| Targets | MEK/ERK | ||
|
RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors
Publications Citing of Biochempartner's Mirdametinib(CAS:391210-10-9) |
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.